Drug · DIN 02484552 · Radiopharmaceutical
LUTATHERA
SINGLE-DOSE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 28, 2024; first marketed December 10, 2019.
- Drug Identification Number (DIN)
- 02484552
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Schedule C
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Lutetium (177lu) oxodotreotide V10XX04
- Class
- Radiopharmaceutical
- Record last updated
- August 10, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LUTETIUM (177LU) OXODOTREOTIDE | 370 MBq | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 28, 2024: NOC 32787New Drug Submission (NDS) · Administrative - Change in Product Ownership
- January 9, 2019: NOC 21712New Drug Submission (NDS)